Actively Recruiting
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Led by Genentech, Inc. · Updated on 2026-04-03
99
Participants Needed
38
Research Sites
498 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
CONDITIONS
Official Title
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed non-small cell lung cancer (NSCLC) stages IB, IIA, IIB, IIIA, or selected IIIB (T3N2 only) based on AJCC/UICC 8th edition staging
- Tumors must have specific biomarker abnormalities including ALK, ROS1, NTRK fusions; BRAF V600 mutation; RET fusion; PD-L1 expression 61% tumor cells; or KRAS G12C mutation
- Measurable disease by RECIST v1.1 criteria
- Tumors must appear solid or subsolid on CT scan, not purely ground glass opacity
- Surgeon evaluation confirming that tumor and lymph nodes can be completely removed and participant is medically operable
- Adequate lung and heart function for surgery
- ECOG Performance Status 0 or 1
- Adequate blood and organ function
- Negative hepatitis B surface antigen and core antibody, or negative HBV DNA if core antibody positive
- Negative hepatitis C antibody or negative HCV RNA if antibody positive
- Male participants must agree to use acceptable contraception
- Female participants of childbearing potential must agree to use acceptable contraception
- For adjuvant therapy: no tumor progression, ECOG 0 or 1, adequate blood and organ function
You will not qualify if you...
- NSCLC classified as T4 due to invasion of mediastinal organs or Stage IIIB with N3 disease
- Prior lung cancer therapy within 2 years including chemotherapy, targeted therapy, immunotherapy, or radiotherapy
- Previous lung cancer diagnosis
- Major surgery within 28 days before starting study treatment
- Other cancers within 3 years except low-risk or cured cases
- Treatment with any investigational drug within 4 weeks before start
- HIV positive with CD4+ count <350 cells/bcl, detectable viral load, recent opportunistic infection, or short antiretroviral therapy
- Severe infection requiring hospitalization within 4 weeks before treatment
- Pregnant, breastfeeding, or planning pregnancy during the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 38 locations
1
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010
Withdrawn
2
City of Hope - Orange County Lennar Foundation Cancer Center
Irvine, California, United States, 92618
Withdrawn
3
USC Norris Cancer Center
Los Angeles, California, United States, 90033
Withdrawn
4
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Withdrawn
5
University of California Los Angeles - Jonsson Comprehensive Cancer Center
Los Angeles, California, United States, 90095
Actively Recruiting
6
The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange
Orange, California, United States, 92868
Actively Recruiting
7
UC Davis Comprehensive Cancer Center
Sacramento, California, United States, 95817
Actively Recruiting
8
UCSF Helen Diller Family CCC
San Francisco, California, United States, 94158
Withdrawn
9
University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center)
Aurora, Colorado, United States, 80045
Withdrawn
10
Yale Cancer Center
New Haven, Connecticut, United States, 06511
Actively Recruiting
11
MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center)
Washington D.C., District of Columbia, United States, 20007
Actively Recruiting
12
Moffitt Cancer Center
Tampa, Florida, United States, 33612
Actively Recruiting
13
Northwestern University
Chicago, Illinois, United States, 60611
Actively Recruiting
14
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois, United States, 60115
Actively Recruiting
15
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois, United States, 60134
Actively Recruiting
16
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois, United States, 60555
Actively Recruiting
17
Boston Medical Center
Boston, Massachusetts, United States, 02118
Withdrawn
18
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
19
University of Michigan
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
20
Karmanos Cancer Institute - Farmington Hills/Weisberg Cancer Treatment Center
Farmington Hills, Michigan, United States, 48334
Withdrawn
21
Mayo Clinic
Rochester, Minnesota, United States, 55905
Actively Recruiting
22
Ellis Fischel Cancer Center
Columbia, Missouri, United States, 65201
Actively Recruiting
23
Siteman Cancer Center - Washington University Medical Campus
St Louis, Missouri, United States, 63108
Actively Recruiting
24
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Actively Recruiting
25
Laura and ISAAC Perlmutter Cancer Center at NYU Langone.
New York, New York, United States, 10016
Actively Recruiting
26
Columbia University Medical Center
New York, New York, United States, 10032
Actively Recruiting
27
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
28
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44016
Withdrawn
29
Ohio State University
Columbus, Ohio, United States, 43210
Actively Recruiting
30
AHN Cancer Institute ? Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15212
Completed
31
Baptist Clinical Research Institute
Memphis, Tennessee, United States, 38120
Actively Recruiting
32
Tennessee Oncology - Nashville
Nashville, Tennessee, United States, 37203
Withdrawn
33
Kelsey Seybold Clnic
Houston, Texas, United States, 77025
Withdrawn
34
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030-4008
Actively Recruiting
35
Baylor College of Medicine
Houston, Texas, United States, 77030
Withdrawn
36
Lumi Research
Kingwood, Texas, United States, 77339
Withdrawn
37
Virginia Cancer Specialists (Fairfax) - USOR
Fairfax, Virginia, United States, 22031
Actively Recruiting
38
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109
Withdrawn
Research Team
R
Reference Study ID Number: ML41591 https://forpatients.roche.com/
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here